9966 — Alphamab Oncology Share News
0.000.00%
Last trade - 00:00- HK$5.54bn
- HK$4.18bn
- CNY566.24m
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)
HK-listed Alphamab hits 2-month high on breast cancer drug licensing deal
Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical (updated)
Brief: Alphamab Oncology Announces Transactions With Pathos AI For JSKN016
Alphamab Oncology licenses overseas rights for cancer therapy to Pathos AI for $2.09 billion
Brief: Alphamab Oncology Announces Approval From CDE For JSKN033 To Initiate A Phase III Clinical Study
Brief: Alphamab Oncology Says Anbenitamab (Kn026) Granted Designation By NMPA For Her2+ Breast Cancer
Alphamab climbs most in over 8 weeks on progress of breast cancer treatment
Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
Brief: Alphamab Oncology Says CEO Buys 554,000 Shares On June 4
Brief: Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint
Brief: Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint
Brief: Alphamab Oncology Posts FY Loss RMB113.9 Million
Brief: Alphamab Oncology Appoints Wang Fei As CFO
Brief: Alphamab Oncology Says Ind Application For Jskn021 Officially Accepted By CDE Of NMPA China
Brief: Alphamab Oncology Says NMPA Accepts NDA For Kn035 First-Line BTC Treatment